Milton Essex SA is a public SPV company established to develop new medical devices. The most important (aimed at the largest market) is the system for reading skin allergy tests. These tests have been the basic tool in detecting allergies for several decades. In clinical practice, no device for computerized reading of allergy tests is currently used. For years, they have been assessed by a doctor only with the use of a ruler or various types of gauges.
Management and Supervisory Board
The Management Board operates on the basis of the Articles of Association and applicable regulations, including the provisions of the Commercial Companies Code. It is composed of two to three members and it runs the Company’s affairs and represents the Company. Members of the Management Board are appointed and dismissed by the Supervisory Board
The Chairperson of the Management Board is appointed and dismissed by the Supervisory Board. The duties of the Supervisory Board include matters specified in the Code of Commercial Companies and in the Articles of Association (item 6.10). The term of office of members of the Supervisory Board is common and lasts three years
Chairperson of the Management Board
Iwona Kaczyńska-Stępień graduated in law from the University of Warsaw and completed her judge training at the Regional Court in Warsaw. Then she was entered on the list of legal advisers of the District Chamber of Legal Advisers in Warsaw. She practiced in a law firm. Between 1995-1998 she was the Director of the Legal Department at Bank Creditanstalt – Bank Austria SA in Warsaw.
In the years 1998-2005 she cooperated with the Warsaw office of the European Institute for Management Studies and as a Partner with the Polish branch of the international advisory firm Glammeron Manner Ltd. Since 2006, she has been a legal advisor in the area of strategic clients and investment funds at ING Bank Śląski SA.
Vice Chairperson of the Management Board, Chief Financial Officer
Radosław Solan is a graduate of the Warsaw School of Economics, Faculty of Finance and Banking. He has an Investment Advisor license No. 172 and a Stockbroker license No. 1586. He started his professional career on the capital market at the Capital Operations Center of Bank Handlowy w Warszawie S.A.
Then he worked at Bankowy Dom Maklerski PKO BP S.A. From April 2004, he was employed at Copernicus Capital Partners, where he created the first independent investment fund company – Copernicus Capital TFI S.A. In 2012-2019 he was a member of the managemennt board of Querton Capital Partners – a business consulting company.
Dr Jacek Stępień
Chairman of the Supervisory Board
Dr Jacek Stępień graduated from higher education and postgraduate studies at the Military Medical Academy and Int. Business School, Institue Française de Gestion, Int. Washington Univ., European Univ. And Koźmiński’s Academy. He has international professional experience as a senior manager gained in concerns and reputable advisory institutions.
Scientist, author of a number of international patents, expert in the field of application of hybrid Hyperspectral imaging methods based on thermodynamic biomarkers in non-invasive medical diagnostics. After completing the MBA program, he is associated with international consulting and strategic consulting, including as an expert of Word Bank / IFC, head of CEE Market Strategy & Sales Forecasting at HQ Northampton for AVON Cosmetics Inc., head of Market Strategy in the CEE structure at Bank Austria / Creditanstalt SA, head of Business Development in the CEE structure PricewaterhouseCoopers (PwC), was the main author business synergy strategy, which allowed the CEE region to be the first in the world to achieve operational readiness.
Prof. Stanisław Kłosowicz
Member of the Supervisory Board
Prof. Stanisław Kłosowicz graduated in chemistry from the Military University of Technology (MUT). He obtained the title of doctor of technical sciences (material engineering), and in 1999 – the title of habilitated doctor of technical sciences (material engineering).
In 2006 he was awarded the title of professor in the field of technical sciences. He has been an academic and didactic worker of the Military University of Technology since 1982. He managed or was the main contractor of 12 research and development projects and a co-author of 4 patents and 4 implementations.
Prof. Edward Stanowski
Member of the Supervisory Board
Prof. Edward Stanowski graduated from the Military Medical Academy in Łódź. For many years he was the head of the General, Oncological, Metabolic and Thoracic Surgery Clinic of the Central Clinical Hospital of the Ministry of National Defense. Former Chief Surgeon of the Polish Army.
An outstanding authority, European-class specialist in the field of minimally invasive surgery and videosurgery. He was awarded the title of Honorary Member of the Society of Polish Surgeons, the Society of Czech Surgeons and the Polish Society of Oncological Surgery.
Member of the Supervisory Board
Jakub Kozioł graduated in law at the Maria Curie-Skłodowska University in Lublin and in project management at the AGH University of Science and Technology in Krakow.
He was entered on the list of attorneys of the Krakow Bar Association, he is associated with the Forystek & Partnerzy Adwokaci i Radcowie Prawni Law Firm; focuses on legal services for business entities, with particular emphasis on the processes of mergers and acquisitions of companies and partnerships as well as capital market law.
Member of the Supervisory Board
Marcin Majka graduated from Accounting at the Faculty of Management and Marketing of the University of Economics in Krakow.
He is the Vice President of the Management Board of Invest House SA.
technology for allergology
Research and development work under which the Company develops a market version of the SkinSense medical system for reading allergy tests. The project is co-financed by the National Center for Research and Development.
quick response to COVID-19
Rapid adaptation of ScanHybrid II technology for COVID-19 prevention and future epidemics. It will be the first medical system of this type. Research and implementation works are funded thanks to the “Fast Track-Coronavirus” program
progress in dermatology
Infra-Skin is another application of the ScanHybird II transducer, which we are currently working on conceptually. In the Knowledge Zone you can read about the statistics of skin cancer and the scientific basis of the Infra-Skin medical system.
Thanks to research with the participation of patients, we have proved the operation and very high efficiency of the ScanHybrid technology. Clinical trials are an extremely complicated and costly process, however, the Company boasts experience in their preparation, organization and documentation of clinical trial results. The project co-financed under the “Fast Track” program proved a high (94%) compliance of the results.
The company is located in the field of high medical technology (MED-TECH) and discounts over 20 years of research experience of its shareholders and scientific partners in the field of application of functional thermodynamic biomarkers in medical diagnostics.
The aim of its establishment was to conduct clinical research and commercialization of an innovative technology of completely non-invasive multispectral imaging of skin tissue, using the latest generation of solutions in the area of: artificial intelligence allowing for full automation of reading of skin allergic tests; machine vision and application of ultra-sensitive photonic systems allowing for wide-spectral scanning of skin tissue including Long-Wave Infra-Red (LWIR) band with exceptional sensitivity and resolution giving an image of even very small changes with a diameter not exceeding 0.3 mm.
In 2020, the Company successfully closed the new share issue. The funds obtained from investors are allocated to technology development. The company has also obtained another grant of almost 7 million PLN. Since December 2020 it has been listed on the New Connect market run by the Warsaw Stock Exchange.
Not only we noticed the problem with the quality of reading skin tests. Recent position papers from the World Allergy Organization emphasize that tests are effective, effective, and safe when properly performed and read. The tests carried out by the Military Medical Institute at the request of the Company showed a very high efficiency of reading the tests by the first version of the device – the so-called early prototype (AUC >94%).
In 2019, Milton Essex SA formed a research and development consortium with the Military Academy of Technology - working on the world's first of its kind, the SkinSENSE™ diagnostic system for digital allergy diagnostics and automatic reading of skin allergy test results. This fully computerized system will greatly facilitate the work of doctors and significantly accelerate the diagnosis of allergies. According to the World Health Organization, allergy is one of the most serious health threats, and its effects are already experienced by almost half of the population of highly developed countries.
In 2020 Milton Essex SA, in response to the situation caused by the coronavirus SARS-COV2 pandemic, formed a second consortium with the WAT Optoelectronics Institute: FaceCOV™, which is developing a scanner to detect the temperature symptoms of infection with infectious agents.
Recently, the Company has completed a program of clinical trials conducted in the Military Medical Institute in Warsaw, under the direction of Prof. Karina Jahnz-Różyk, as part of the project 3OIR.01.01.01-00-0162/15 entitled "Clinical trials in the Military Medical Institute in Warsaw". "FIRIMAS - Solution for functional infrared imaging of the skin allergic response" co-financed by a grant from the National Centre for Research and Development under Sub-measure 1.1.1 "Industrial research and development work carried out by enterprises", Operational Programme Intelligent Development 2014-2020.